Erratum: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis (Blood (2017)130: 5 (597-605)DOI: 10.1182/blood-2017-03-771220)
Articolo
Data di Pubblicazione:
2020
Abstract:
In “Acknowledgments” on page 604, support from the National Institutes of Health for Jeffrey A. Zonder (grant P30 CA022453) is not acknowledged. The error has been corrected in the online version of the article.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Sanchorawala, V; Palladini, G; Kukreti, V
Link alla scheda completa:
Pubblicato in: